However, further research is required to fully confirm the impact of PACAP/VIP in dampening ER stress, elucidate the mechanisms by which it could occur and, by extension, the ability to use this capacity as a therapeutic opportunity in attempts to prevent neurodegeneration in MS and perhaps other demyelinating disorders [57]. This evidence concerns the gene VIP and myeloid sarcoma.